NCI-H460 Transfection

* This product is for research use only. Not intended for use in the treatment or diagnosis of disease.

Lung cancer accounts for more than one-third of cancer-related deaths and is one of the deadliest cancers worldwide. In 2015, 221,200 people were diagnosed with lung cancer in the United States, of which 158,040 died. Statistically, approximately 85% of lung cancer cases are diagnosed as non-small cell lung cancer, including large cell carcinoma, adenocarcinoma, and squamous cell carcinoma. NCI-H460 (human large cell lung cancer cells) is also known as NCI.H460; H460; H-460; NCIH460; NCI-HUT-460; NCI-460, and it was discovered by AF Gazdar and his colleagues in 1982 from a man with large cell lung cancer. This oncogenic cell line exhibits an epithelial morphology and expresses p53 mRNA like normal lung tissue. The NCI-H460 cell line is also unique in that it shows no obvious structural DNA abnormalities. In addition to being negative for neurofilament triad protein, NCI-H460 cells stained positive for poikilins and keratin.

BOC Sciences offers efficient transfection kits for NCI-H460 lung cancer cell line.

Product Information

Catalog Number BT-000049
ContentsNCI-H460 Transfection Kit includes NCI-H460 transfection reagent and transfection enhancer.
StorageStore at 4℃. If stored properly, the reagent is stable for up to 6 months.
ShippingThe NCI-H460 transfection reagent is supplied in liquid form and is transported at ambient temperature.
Transfection EfficiencyAt least 90% efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Use LimitationsFor research use only.

Features

  • Novel chemical formulation for transfection of NCI-H460 cells.
  • Unique lipid and polymer formulation ensures maximum transfection efficiency and cell viability.
  • High convenience and high-temperature compatibility.
  • Easy-to-use protocol: Just mix nucleic acids with reagent to form complexes and simply add mixture to cells.

Reference

  1. Townsend MH; et al. Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane. Onco Targets Ther. 2017; 10: 1921-1932.

Related Sections: